Prolonged remission of platinum-refractory ovarian cancer with docetaxel: Brief report and review of literature

European Journal of Gynaecological Oncology

Volumn 18, Issue 5, 1997, Pages 341-342

  Balat, O ^a   Kudelka, A P ^a   Edwards, C L ^a   Verschraegen, C F ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Docetaxel; Ovarian cancer; Prolonged complete remission

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; HUMAN; OVARY CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; REMISSION INDUCTION; SALVAGE THERAPY; TAXOIDS;

EID: 0030823133     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Boring C. C., Squires T, S., Tong T.: "Cancer statistics". C.A. Cancer J. Clin., 1994, 44, 7.
2. Kavanagh J. J., Kudelka A.: "Systemic therapy for gynecologic cancer". Curr. Opin. Oncol., 1993, 5, 891.
3. Ozols R. F., Young R. C.: "Chemotherapy of ovarian cancer". Semin. Oncol., 1991, 18, 222.
4. Pazdur R., Kudelka A. P., Kavanagh J. J., Phillip R., Cohens P. R., Raber M. N et al.: "The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere)". Cancer Treat. Rev., 1993, 19, 351.
5. Holmes F. A., Kudelka A. P., Kavanagh J. J., Huber M. H., Ajani J. A., Valero V. et al.: "Current status of clinical trials with paclitaxel and docetaxel". In: Gorg G. I., Chen T. C., Ojima I. (eds.), ACS Symposium. Taxane anticancer agent basic sciences and current status, 1995, 3, 31.
6. Pazdur R., Newman R. A., Newman B. M., Fuentes A., Benvenuto J., Bready B. et al.: "Phase I trial of taxotere: five-day schedule". J. Natl Cancer Inst., 1992, 84, 1781.
7. Galindo E., Kavanagh J., Fossella F., Valero V., Bedikian Y., Pazdur R. et al.: "Docetaxel (taxotere) toxicities: analysis of a single institution experience of 168 patients (623 courses)". Proc. Amer. Soc. Clin. Oncol., 1994, 13, A452 (abstract)
8. Piccart M. J., Gore M., Ten Bokkel Huinink W., Van Dosterom A., Verweij J., Wanders J. et al.: "Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer". J. Natl. Cancer Inst., 1995, 87, 676.
9. Francis P., Schneider J., Hann L., Balmaceda C , Barakat R., Phillips M. et al.: "Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer". J. Clin. Oncol., 1994, 2, 2301.
10. Kavanagh J. J., Kudelka A. P., Freedman R. S., Edwards C. L., Pazdur R., Bellet R. et al.: "A phase II trial of Taxotere in ovarian cancer patients refractory to cisplatin/carbplatin therapy". Proc. Amer. Soc. Clin. Oncol., 1993, 2, 259 (abstract).
11. Aapro M , Pujade-Lauraine E., Lhomme C., Lentz M. A , Le Bail N., Fumoleau P. et al.: "Phase II study of Taxotere in ovarian cancer". Proc. Amer. Soc. Clin. Oncol., 1993, 12, 256 (abstract).
12. Kavanagh J. J., Kudelka A. P., Freedman R., Edwards C., Bayssas M , Bellet R. et al.: "Taxotere (Docetaxel): activity in platin refractory ovarian cancer and amelioration of toxicity". Proc. Amer. Soc. Clin. Oncol., 1994, 13, 237 (abstract).
13. Kavanagh J. J., Kudelka A. P., Gonzalez de Leon C., Tresurosol D., Hord M., Finnegan M. B. et al.: "Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum", Clin. Cancer Res., 1996, 2, 73.